Research
Hormonal
Metabolic disruptors can cause transgenerational inheritance of obesity and metabolic dysfunction, affecting offspring (F3 generation) who were never directly exposed to the chemical.
Be aware that your metabolic health may be influenced by your parents' and grandparents' environmental exposures. While you cannot change the past, you can protect your children by minimizing their exposure to plastics and environmental chemicals.
ModerateSupportsMEDIUM confidence
The effects of prenatal exposure to some obesogens persist until at least the F3 generation... The F3 is the first generation that has not received any direct chemical exposure; therefore, effects observed in F3 and beyond are considered to be transgenerational and permanent.
Why this rating
Strong evidence in animal models (mice), but human transgenerational evidence is still emerging.
Source
Parma consensus statement on metabolic disruptors
Jerrold J. Heindel et al. · Environmental Health · 2015
DOI 10.1186/s12940-015-0042-7
narrative_reviewCited 216×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Exposure to environmental metabolic disruptors (e.g., BPA, phthalates, TBT) during critical developmental windows (in utero, early childhood) permanently alters metabolic programming, increasing susceptibility to obesity, diabetes, and metabolic syndrome later in life.Good
- Reducing exposure to environmental chemicals and improving nutrition during development can prevent obesity and metabolic diseases.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →